MARAVAI LIFESC.HLD.A -01
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Producti… Read more
MARAVAI LIFESC.HLD.A -01 (MAR) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, MARAVAI LIFESC.HLD.A -01 (MAR) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MARAVAI LIFESC.HLD.A -01 - Net Assets Trend (None–None)
This chart illustrates how MARAVAI LIFESC.HLD.A -01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MARAVAI LIFESC.HLD.A -01 (None–None)
The table below shows the annual net assets of MARAVAI LIFESC.HLD.A -01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to MARAVAI LIFESC.HLD.A -01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
MARAVAI LIFESC.HLD.A -01 Competitors by Market Cap
The table below lists competitors of MARAVAI LIFESC.HLD.A -01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Feymer Technology Co Ltd
SHG:688350
|
$264.42 Million |
|
PYC Therapeutics Ltd
AU:PYC
|
$264.67 Million |
|
B.Grimm Power Public Company Limited
BK:BGRIM
|
$264.68 Million |
|
Tellgen Corp
SHE:300642
|
$264.70 Million |
|
Ginwa Enterprise Group Inc
SHG:600080
|
$264.23 Million |
|
Qingdao NovelBeam Technology Co. Ltd. A
SHG:688677
|
$264.14 Million |
|
Guangdong Huiyun Titanium Industry
SHE:300891
|
$264.10 Million |
|
Moso Power Supply Technology Co Ltd
SHE:002660
|
$264.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MARAVAI LIFESC.HLD.A -01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares MARAVAI LIFESC.HLD.A -01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently MARAVAI LIFESC.HLD.A -01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares MARAVAI LIFESC.HLD.A -01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MARAVAI LIFESC.HLD.A -01 (MAR) | €- | N/A | N/A | $264.39 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |